GLPwatch
Papers (10588)
Page 161 of 177, ranked by citation count.
- Liraglutide Effectiveness: Is There a Real-Word Clinical Benefit?
- [Pharmacological treatment of obstructive sleep apnea syndrome].
- SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review.
- The glucagon-like peptide-1 receptor agonist, Ex4, reduces intromission in sexually experienced male mice.
- NewDrugs 2017, part 2.
- [Liraglutide reduces biomarkers and vascular risk in patients with diabetes mellitus type 2].
- Therapeutic development in MASH: From accelerated approval to cirrhosis trial innovation.
- Liraglutide alleviates postoperative cognitive impairment via NRF2/NLRP3 signal pathway in aged mice.
- Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.
- A second case of liraglutide-type localised amyloidosis.
- Web Exclusive. Annals On Call - Comparison of Dose Escalation Versus Switching to Tirzepatide When Diabetes Control Is Inadequate With Dulaglutide.
- Response by Kosiborod et al to Letter Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial".
- Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes.
- Hepatic portal venous gas in a patient with diabetes on GLP-1 receptor agonist and alpha-glucosidase inhibitor.
- Exploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends.
- Cross-sectional analysis of the reliability and engagement metrics of YouTube videos on semaglutide for weight loss.
- [Effects of liraglutide combined with vitamin D on non-alcoholic fatty liver induced by high fat in mice and its mechanism].
- [Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy].
- Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
- Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis.
- Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.
- Addressing patient concerns about the 'newness' and long-term safety of GLP-1 receptor agonists: A clinician's guide to counseling.
- Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes: An Observational Health Data Sciences and Informatics Network Study.
- Evaluating The Long-Term Cost-Effectiveness Of Liraglutide 1.2 Mg And Exenatide In Patients With Type 2 Diabetes Mellitus.
- Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study.
- Summary for Patients: Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide.
- Response to the letter from Horowitz et al. to the Editor relating to the publication 'Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes' by Dahl et al.
- Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
- [Liraglutide in the treatment of diabetes type 2].
- Low discontinuation rate of tirzepatide treatment in Japanese patients with diabetes mellitus; importance of traditional Japanese diet.
- New Injectable Drug for Type 2 Diabetes.
- Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.
- Tirzepatide for Obstructive Sleep Apnea: A Novel Therapeutic Promise and the Perioperative Considerations.
- A retrospective audit of weight loss and health outcomes following bariatric surgery at a tertiary public hospital.
- The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials.
- Assessment of lixisenatide-induced nephropathy in chick embryos: Implications for prevention of diabetic kidney disease.
- Case Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantation.
- Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies.
- Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs).
- Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.
- Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin or Exenatide in Patients With Inadequately Controlled Type 2 Diabetes On Oral Antidiabetic Drugs In Greece.
- Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- Obesity medications and acquired hypothalamic obesity in adults: A two-case experience.
- Beyond Patient Factors: Are we Missing the Surgical Context in Comparing Tirzepatide and Semaglutide Post-CABG?
- [Basal insulin and GLP-1 agonist potentiate each other (interview by Dr. med Dirk Einecke)].
- Obesity and heart failure-the role of GLP-1 receptor agonists.
- Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub-analysis of Hokkaido-TZP study data.
- Evaluating the pharmacotherapy of tirzepatide in patients with type 2 diabetes: The consideration of systemic metabolism.
- Tirzepatide attenuates doxorubicin-induced cardiotoxicity via mitochondrial function improvement.
- Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial.
- Major Adverse Cardiovascular Event Outcomes in Patients With Obesity and Type 2 Diabetes Undergoing Medical Weight Management.
- Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential.
- Tirzepatide in type 1 diabetes: beyond mere weight loss.
- [in process].
- [The extra-glycemic effects of liraglutide: focus on cardiometabolic markers].
- [The antidiabetic drug liraglutide lowers risk of cardiac death].
- Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.
- Effect of glucagon-like peptide-1 analogue liraglutide on primary cultures of rat hepatocytes isolated from lean and steatotic livers.
- [Degludec/liraglutide] fixed combination as a therapy alternative].
- Tirzepatide retention in iWAT with mesoporous polydopamine encapsulation enhances weight loss through leptin receptor signaling.